POLYMED - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.3
| Stock Code | POLYMED | Market Cap | 12,985 Cr. | Current Price | 1,281 ₹ | High / Low | 2,938 ₹ |
| Stock P/E | 37.4 | Book Value | 285 ₹ | Dividend Yield | 0.27 % | ROCE | 18.2 % |
| ROE | 14.2 % | Face Value | 5.00 ₹ | DMA 50 | 1,437 ₹ | DMA 200 | 1,793 ₹ |
| Chg in FII Hold | -0.36 % | Chg in DII Hold | 0.31 % | PAT Qtr | 83.4 Cr. | PAT Prev Qtr | 89.0 Cr. |
| RSI | 42.7 | MACD | -46.0 | Volume | 1,71,071 | Avg Vol 1Wk | 1,52,734 |
| Low price | 1,210 ₹ | High price | 2,938 ₹ | PEG Ratio | 1.21 | Debt to equity | 0.08 |
| 52w Index | 4.09 % | Qtr Profit Var | -2.04 % | EPS | 33.8 ₹ | Industry PE | 33.9 |
📊 Analysis: POLYMED trades at ₹1,281, well below both 50 DMA (₹1,437) and 200 DMA (₹1,793), showing strong short-term weakness. RSI at 42.7 and MACD negative (-46.0) confirm bearish momentum. Volume is slightly above weekly average, but price action remains weak. Fundamentals are moderate with ROCE 18.2% and ROE 14.2%, but valuation is stretched (P/E 37.4 vs industry 33.9). Intraday bias is bearish-to-neutral with limited upside potential.
💡 Optimal Buy Price: ₹1,270–1,280 if price stabilizes near support.
🎯 Profit Exit Levels: ₹1,300 (first target), ₹1,320 (second target).
🛡️ Stop-Loss: ₹1,260 (below intraday support).
⏱️ If Already Holding: Exit near ₹1,300–1,320 if momentum weakens. If price breaks below ₹1,260 with volume spike, cut position immediately.
✅ Positive
- EPS at ₹33.8 shows earnings presence.
- DII holdings increased (+0.31%).
- PEG ratio at 1.21 indicates reasonable valuation relative to growth.
- Debt-to-equity ratio at 0.08, very low leverage.
⚠️ Limitation
- Stock trades below both 50 DMA and 200 DMA.
- Weak momentum indicators (RSI 42.7, MACD -46.0).
- Quarterly PAT declined from ₹89 Cr. to ₹83.4 Cr. (-2.04%).
- High P/E (37.4) compared to industry average (33.9).
📉 Company Negative News
- FII holdings decreased (-0.36%).
- Sequential profit decline may weigh on sentiment.
📈 Company Positive News
- DII inflows (+0.31%) show domestic support.
- Strong fundamentals with ROCE 18.2% and ROE 14.2%.
🏭 Industry
- Industry P/E at 33.9, POLYMED trades at 37.4, showing slight overvaluation.
- Medical devices sector demand remains resilient, supported by healthcare expansion.
🔎 Conclusion
POLYMED is a high-risk intraday candidate. Momentum indicators suggest caution, with weak price action and declining profits. Best approach: buy only near ₹1,270–1,280 if support holds, exit at ₹1,300–1,320, and protect downside with stop-loss at ₹1,260.
Would you like me to extend this into a peer benchmarking overlay with other medical device/pharma suppliers (e.g., Poly Medicure peers like Opto Circuits, Transasia, or global medtech players) so you can see if POLYMED is underperforming or showing relative strength intraday?